To hear about similar clinical trials, please enter your email below
Trial Title:
Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
NCT ID:
NCT06076252
Condition:
Ampullary Cancer
Bile Duct Cancer
Pancreas Cancer
Duodenum Cancer
Conditions: Official terms:
Pancreatic Neoplasms
Bile Duct Neoplasms
Cholangiocarcinoma
Duodenal Neoplasms
Pancreatic Fistula
Fistula
Study type:
Interventional
Study phase:
N/A
Overall status:
Enrolling by invitation
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
Single (Outcomes Assessor)
Intervention:
Intervention type:
Procedure
Intervention name:
Modified Blumgart Anastomosis in LPD
Description:
This study is a clinical study designed by parallel control, the test group is LPD
patients with modified Blumgart anastomosis and the control group is LPD patients with
conventional Blumgart anastomosis
Arm group label:
Modified Blumgart Anastomosis of LPD
Intervention type:
Procedure
Intervention name:
conventional Blumgart anastomosis in LPD
Description:
This study is a clinical study designed by parallel control, the test group is LPD
patients with modified Blumgart anastomosis and the control group is LPD patients with
conventional Blumgart anastomosis
Arm group label:
Conventional Blumgart Anastomosis of LPD
Summary:
The incidence rate and mortality rate of periampullary cancer at home and abroad both
show an increasing trend, seriously affecting the health level of the people.
Pancrecoduodenectomy (PD) is the only effective treatment for periampullary cancer.
However, due to the complex technology and difficulty of PD surgery, laparoscopic
pancreaticoduodenectomy (LPD) is more difficult, and the postoperative mortality can
reach 5%. The important reason is the most serious complication- -pancreatic fistula. The
occurrence of pancreatic fistula is related to many factors, and the most critical factor
is the method and technology of pancreatico-intestinal anastomosis, so the improvement
and innovation of pancreaticoco-intestinal anastomosis technology has always been a hot
topic in surgical clinical research. Blumgart Pancreatic anastomosis was originally
created by Professor L.H.Blumgart in the United States, and was widely used in OPD due to
its low incidence of pancreatic fistula. However, the traditional Blumgart anastomosis is
complicated and is not suitable for application in LPD. According to our own experience,
our team simplified and improved the traditional Blumgart anastomosis to OPD, and through
retrospective study, it has the advantages of reducing the incidence of pancreatic
fistula. However, the application value in LPD still needs to be further discussed.
Therefore, this study intends to use a prospective randomized controlled trial, using the
LPD patients with traditional Blumgart pancreatecointestinal anastomosis as the control
group, and the LPD patients with modified Blumgart pancreatecointestinal anastomosis as
the test group, compare the clinical relevant indicators and the incidence of
postoperative complications, and explore whether the application value in LPD can truly
simplify the surgical procedure and ensure the lower incidence of pancreatic leakage.
Detailed description:
This study intends to use a prospective randomized controlled trial, the LPD patients
with traditional Blumgart anastomosis as the control group, design the LPD patients with
modified Blumgart anastomosis as the test group, by comparing the clinical correlation
index and the rate of postoperative complications in LPD can truly simplify the surgical
procedure and ensure the lower rate of pancreatic leakage.
The following steps will be followed:
1. Patients who met the inclusion criteria and did not meet the exclusion criteria
underwent modified Blumgart anastomosis according to the randomization LPD surgery
group (test group) or LPD surgery group with conventional Blumgart
pancreatecreenterostomy (control group).
2. The following common LPD procedure was used in the test and control groups: ①
Preoperative preparation and anesthesia mode Preoperative gastric tube, urinary tube
and central venous channel; general anesthesia ② Same surgical procedure:
Establishment of artificial pneumoperitoneum and operating hole anatomical
exploratory specimen resection and reconstruction of digestive tract (biliary
intestine kiss Combination, gastrointestinal anastomosis) drain placement.
3. In the test group, the pancreatic intestine anastomosis in the LPD Combined, the
control group used conventional Blumgart pancreatestatic anastomosis.
4. Both postoperative groups were routinely given anti-infection, gastric mucosa
protection, somatostatin, and nutritional supportive therapy. After the first Remove
gastric tube and urinary catheter on 3 days, instructed patients to eat cold liquid
food and ambulation; somatostatin was stopped on postoperative day 5, The upper
abdominal CTA was reviewed, and the remaining treatment plans were formulated
according to the actual situation of the patient. Postoperative numbers 1,3,5, and
For 7 days, the relevant drainage indexes, daily drainage rate, drainage properties
and amylase content were reviewed.
5. If the patient can be discharged with the following conditions: the general
condition is good, and the normal diet and intestinal function are basically
restored; Body temperature was normal and the abdominal examination showed no
positive signs; relevant laboratory results were almost normal; CTA Significant
abdominal effusion and other abnormalities; postoperative abdominal incision healed
well.
6. After discharge, pay attention to their appetite, spirit, urine and feces, and
drainage tube (discharged with drainage tube). Patients without special discomfort
were returned to the hospital for review once at 1and 3 months after surgery.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
Radically resectable stage I - III low periampullary carcinoma in patients, And all met
the following criteria:
1. age 18-75 years;
2. imaging (upper abdominal MRI, MRCP / CT / CTA) diagnosis of periampullary (duodenal
papilla, ampulla, inferior common bile duct, pancreatic head);
3. MDT discussion of tumor invasion of large vessels (SMA, CA, CHA/SMV, PV) resectable;
4. endoscopic duodenal ultrasound diagnosis of periampullary carcinoma;
5. endoscopic biopsy pathology confirmation of carcinoma (not essential);
6. preoperative stage within T3N1;
7. no evidence of distant metastasis;
8. cardiopulmonary and liver and kidney function can tolerate surgery;
9. patients and family members can understand and willing to participate in this study,
Provided the written informed consent.
Exclusion Criteria:
1. Diagnosis of malignant tumors in other sites;
2. ASA grade IV and / or ECOG physical strength status score> 2 points;
3. Patients with severe liver and kidney function, cardiopulmonary function,
coagulation dysfunction or severe basic diseases who cannot tolerate surgery;
4. Have an uncontrolled preoperative infection;
5. Pregnant or lactating women;
6. A history of serious mental illness;
7. Patients with other clinical and laboratory conditions considered by the
investigator are not suitable to participate in this trial
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
The Affiliated Hospital of Guangdong Medical University
Address:
City:
Zhanjiang
Country:
China
Start date:
July 1, 2023
Completion date:
August 31, 2028
Lead sponsor:
Agency:
Affiliated Hospital of Guangdong Medical University
Agency class:
Other
Source:
Affiliated Hospital of Guangdong Medical University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06076252